Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification

Christian Morath, Changli Wei, Stephan Macher-Goeppinger, Vedat Schwenger, Martin Zeier, Jochen Reiser

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Circulating soluble urokinase receptor (suPAR) was recently identified as one of the causes responsible for native and recurrent focal segmental glomerulosclerosis (FSGS) through overactivation of podocyte β3 integrin. Here, we discuss the management of a patient with very high suPAR serum levels and FSGS recurrence. The suPAR reduction using plasmapheresis and immunoadsorption allowed for lowering of suPAR and reduced podocyte β3 integrin activation and proteinuria. The patient is successfully weaned to bimonthly suPAR removal treatments with improved renal parameters. In summary, we provide an approach for the successful management of severe recurrent FSGS using available therapies with biomarker guidance.

Original languageEnglish (US)
Pages (from-to)226-229
Number of pages4
JournalAmerican Journal of Therapeutics
Volume20
Issue number2
DOIs
StatePublished - Mar 2013
Externally publishedYes

Keywords

  • Apheresis
  • Circulating factor
  • FSGS
  • Transplantation

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification'. Together they form a unique fingerprint.

Cite this